Skip to main content

Ani Pharmaceuticals Inc

ANIP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001023024

In the last 90 days, Ani Pharmaceuticals Inc insiders filed 0 open-market purchases and 11 sales; 321 institutions reported holding it in 13F filings for Q2 2026, worth $2.27B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Ani Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
11 filings
5 insiders, $2.18M in total
Insiders trading
5
Net value
−$2.18M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Ani Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Ani Pharmaceuticals Inc
NameTitleLast reported holdingLast filingFilings, past year
Lalwani NikhilPRESIDENT & CEO339,089Sep 16, 20267
Thoma JeanneDirector26,762Sep 14, 20262
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.73,924Sep 14, 202615
Carey Stephen P.SVP & CFO171,843Sep 1, 202610
Gosebruch Henry ODirector6,662Aug 27, 20261
Gutwerg OriSVP, GENERICS75,534Aug 11, 20267
Haughey ThomasDirector38,878Jun 10, 20261
Tannenbaum Renee PDirector29,514Jun 10, 20262
Pera Antonio RDirector27,017Jun 10, 20261
Leonard Matthew JDirector11,221Jun 10, 20261
Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS38,271May 13, 20265
Walsh Patrick DDirector38,432May 13, 20263
Mutz ChristopherHEAD OF RARE DISEASE91,309Mar 13, 20267
Davis KristaSVP, CHIEF HR OFFICER51,946Mar 10, 20266
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS101,056Mar 2, 20262
Gassert ChadSVP - CORP. DEV. & STRATEGY74,916Mar 2, 20264
Marken James G.SVP OPS & PROD DEV117,829Jun 11, 20240
Meridian Venture Partners II LP10% Owner1,819,259Aug 16, 20230
Brown Robert E. JR10% Owner1,819,259Aug 16, 20230
Meridian Venture Partners II, Co.10% Owner1,819,259Aug 16, 20230
Meridian Venture Partners II GP, L.P.10% Owner1,819,259Aug 16, 20230
Nash DavidDirector38,561May 24, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 16, 2026 (view filing)4:20 PM ETSep 151 dayLalwani NikhilPRESIDENT & CEOSSale−5.40K$71.00−$383.4K−1.6%339.1K after10b5-1
Sep 14, 2026 (view filing)8:57 PM ETSep 113 daysThoma JeanneDirectorSSale−1.00K$71.53−$71.5K−3.6%26.8K after10b5-1
Sep 14, 2026 (view filing)8:56 PM ETSep 14Same dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−500$70.79−$35.4K−0.7%73.9K after10b5-1
Sep 1, 2026 (view filing)6:18 PM ETAug 311 dayCarey Stephen P.SVP & CFOSSale−2.85K$72.80−$207.5K−1.6%171.8K after10b5-1
Aug 26, 2026 (view filing)6:15 PM ETAug 251 dayLalwani NikhilPRESIDENT & CEOSSale−5.40K$74.30−$401.2K−1.5%344.5K after10b5-1
Aug 13, 2026 (view filing)4:32 PM ETAug 13Same dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−500$75.48−$37.7K−0.7%74.4K after10b5-1
Aug 11, 2026 (view filing)8:57 PM ETAug 101 dayGutwerg OriSVP, GENERICSSSale−3.16K$77.00−$243.5K−4.0%75.5K after
Jul 30, 2026 (view filing)4:02 PM ETJul 291 dayCarey Stephen P.SVP & CFOSSale−2.85K$81.36−$231.9K−1.6%174.7K after10b5-1
Jul 14, 2026 (view filing)4:02 PM ETJul 131 dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−500$81.84−$40.9K−0.6%77.4K after10b5-1
Jul 6, 2026 (view filing)9:40 PM ETJul 24 daysCarey Stephen P.SVP & CFOSSale−3.31K$86.00−$284.9K−1.8%177.5K after10b5-1
Jun 30, 2026 (view filing)Jun 291 dayCarey Stephen P.SVP & CFOSSale−2.85K$84.12−$239.7K−1.6%177.5K after10b5-1
Jun 15, 2026 (view filing)Jun 123 daysCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−500$82.03−$41.0K−0.6%77.9K after10b5-1
Jun 10, 2026 (view filing)Jun 82 daysHaughey ThomasDirectorSSale−2.00K$80.88−$161.8K−4.9%38.9K after10b5-1
Jun 9, 2026 (view filing)Jun 54 daysCarey Stephen P.SVP & CFOSSale−3.31K$80.00−$265.0K−1.8%180.4K after10b5-1
May 13, 2026 (view filing)May 13Same dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−500$78.16−$39.1K−0.6%78.4K after10b5-1
May 13, 2026 (view filing)May 121 dayGutwerg OriSVP, GENERICSSSale−2.77K$79.50−$220.4K−3.4%78.7K after
May 13, 2026 (view filing)May 112 daysLalwani NikhilPRESIDENT & CEOSSale−55.0K$77.57−$4.27M−13.6%349.9K after
May 13, 2026 (view filing)May 11-132 daysWalsh Patrick DDirectorSSale−14.0K$80.66−$1.13M−26.7%38.4K after2 lots
May 13, 2026 (view filing)May 121 dayRowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDSSSale−459$79.21−$36.4K−1.2%38.3K after
Apr 13, 2026 (view filing)Apr 13Same dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−500$77.95−$39.0K−0.6%78.9K after10b5-1
Mar 13, 2026 (view filing)Mar 13Same dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−500$72.62−$36.3K−0.6%79.4K after10b5-1
Mar 13, 2026 (view filing)Mar 13Same dayMutz ChristopherHEAD OF RARE DISEASESSale−3.16K$71.64−$226.5K−3.3%91.3K after10b5-1
Mar 13, 2026 (view filing)Mar 112 daysRowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDSSSale−4.77K$74.91−$357.5K−11.0%38.7K after
Mar 10, 2026 (view filing)Mar 6-94 daysDavis KristaSVP, CHIEF HR OFFICERSSale−6.57K$74.33−$488.5K−11.2%51.9K after2 lots10b5-1
Mar 10, 2026 (view filing)Mar 6-94 daysMutz ChristopherHEAD OF RARE DISEASESSale−5.72K$74.19−$424.6K−5.7%94.5K after2 lots10b5-1
Mar 5, 2026 (view filing)Mar 5Same dayCarey Stephen P.SVP & CFOSSale−7.31K$75.50−$552.0K−3.8%185.5K after2 lots
Mar 4, 2026 (view filing)Mar 22 daysMutz ChristopherHEAD OF RARE DISEASESSale−417$74.00−$30.9K−0.4%103.5K after10b5-1
Mar 4, 2026 (view filing)Mar 31 dayGutwerg OriSVP, GENERICSSSale−2.06K$76.50−$157.6K−2.4%84.8K after
Mar 3, 2026 (view filing)Mar 3Same dayWalsh Patrick DDirectorSSale−6.00K$74.23−$445.4K−10.3%52.4K after
Feb 23, 2026 (view filing)Feb 19-204 daysDavis KristaSVP, CHIEF HR OFFICERSSale−3.81K$77.74−$296.5K−7.2%49.3K after2 lots10b5-1
Feb 23, 2026 (view filing)Feb 203 daysMutz ChristopherHEAD OF RARE DISEASESSale−5.32K$78.02−$415.3K−5.9%84.8K after10b5-1
Feb 17, 2026 (view filing)Feb 134 daysCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−500$76.80−$38.4K−0.7%69.3K after10b5-1
Feb 17, 2026 (view filing)Feb 125 daysMutz ChristopherHEAD OF RARE DISEASESSale−7.03K$76.55−$538.3K−7.1%92.6K after10b5-1
Jan 14, 2026 (view filing)Jan 131 dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−500$84.33−$42.2K−0.7%74.4K after10b5-1
Dec 19, 2025 (view filing)Dec 181 dayDavis KristaSVP, CHIEF HR OFFICERSSale−1.62K$82.40−$133.7K−2.7%58.6K after10b5-1
Dec 12, 2025 (view filing)Dec 12Same dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−400$82.32−$32.9K−0.5%74.9K after10b5-1
Dec 9, 2025 (view filing)Dec 54 daysTannenbaum Renee PDirectorSSale−1.80K$81.15−$146.1K−6.7%25.2K after
Nov 17, 2025 (view filing)Nov 134 daysWalsh Patrick DDirectorSSale−8.64K$86.88−$750.9K−12.3%61.4K after
Nov 14, 2025 (view filing)Nov 131 dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−400$87.27−$34.9K−0.5%75.3K after10b5-1
Nov 14, 2025 (view filing)Nov 12-132 daysGassert ChadSVP - CORP. DEV. & STRATEGYSSale−14.7K$89.06−$1.31M−8.5%158.5K after2 lots
Oct 14, 2025 (view filing)Oct 131 dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−400$90.09−$36.0K−0.5%75.7K after10b5-1
Sep 22, 2025 (view filing)Sep 193 daysDavis KristaSVP, CHIEF HR OFFICERSSale−1.00K$98.04−$98.0K−1.6%60.2K after10b5-1
Sep 15, 2025 (view filing)Sep 123 daysCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−400$98.42−$39.4K−0.5%76.1K after10b5-1
Sep 4, 2025 (view filing)Sep 31 dayPera Antonio RDirectorSSale−7.29K$94.94−$692.3K−24.3%22.7K after
Aug 26, 2025 (view filing)Aug 251 dayLeonard Matthew JDirectorSSale−2.53K$90.62−$229.1K−26.9%6.86K after
Aug 25, 2025 (view filing)Aug 223 daysDavis KristaSVP, CHIEF HR OFFICERSSale−1.76K$91.10−$160.6K−2.7%62.9K after
Aug 22, 2025 (view filing)Aug 20-212 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−100.0K$90.36−$9.04M−18.8%431.9K after2 lots
Aug 20, 2025 (view filing)Aug 182 daysThoma JeanneDirectorSSale−21.5K$89.15−$1.92M−47.9%23.4K after2 lots
Aug 20, 2025 (view filing)Aug 20Same dayPera Antonio RDirectorSSale−5.42K$89.73−$486.4K−15.3%30.0K after
Aug 18, 2025 (view filing)Aug 153 daysGassert ChadSVP - CORP. DEV. & STRATEGYSSale−20.0K$86.97−$1.74M−10.4%173.2K after